WEEI/NESN Jimmy Fund Radio-Telethon

WEEI/NESN Jimmy Fund Radio-Telethon

By AudacySports
Download on the App Store

WEEI/NESN Jimmy Fund Radio-Telethon episodes

  • OMF - Jennifer Geoffroy, 53, multiple myeloma, Pittstown, NJ with Dr. Kenneth Anderson, Program Director, Jerome Lipper Multiple Myeloma Center and Physician at LeBow Institute for Myeloma Therapeutic
    Ten years ago, at 43 years old, Jennifer was diagnosed with multiple myeloma during an annual routine physical. She was an active, healthy young mother with no symptoms of cancer.  
    She has since undergone a stem cell transplant and now receives medication and labs every 3 months. Jennifer is still being treated by Dr. Anderson, who she claims saved her life and the lives of her four daughters. 
    Jennifer chose to be treated at Dana-Farber because of its excellent reputation. She also likes that her team solely focuses on multiple myeloma and has several experts in the field. 
    In her spare time, Jennifer loves to exercise, either going on walks or bike rides, take vacation, and spend time with her family. 
    She is supported at home by her husband, Glenn; her 21-year-old daughter, Danielle, and her 13-year-old identical triplets, Rachel, Nicole, and Alexa.
    Dr. Anderson serves as chief of the Division of Hematologic Neoplasia, director of the Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber.
    In his four decades of practice and research, including 32 years at Dana-Farber, Anderson has played a central role in transforming myeloma, a cancer of the bone marrow, from a near immediate death sentence to, in many cases, a chronic, manageable illness.
    From the 1970s through the ‘90s, not a single new myeloma drug made it into clinical practice. But during the last decade, Anderson has helped shepherd multiple new drugs from laboratory bench through regulatory approval and to the patient bedside.
    6 min
  • OMF - Jennifer Geoffroy, 53, multiple myeloma, Pittstown, NJ with Dr. Kenneth Anderson, Program Director, Jerome Lipper Multiple Myeloma Center and Physician at LeBow Institute for Myeloma Therapeutic
    Ten years ago, at 43 years old, Jennifer was diagnosed with multiple myeloma during an annual routine physical. She was an active, healthy young mother with no symptoms of cancer.  
    She has since undergone a stem cell transplant and now receives medication and labs every 3 months. Jennifer is still being treated by Dr. Anderson, who she claims saved her life and the lives of her four daughters. 
    Jennifer chose to be treated at Dana-Farber because of its excellent reputation. She also likes that her team solely focuses on multiple myeloma and has several experts in the field. 
    In her spare time, Jennifer loves to exercise, either going on walks or bike rides, take vacation, and spend time with her family. 
    She is supported at home by her husband, Glenn; her 21-year-old daughter, Danielle, and her 13-year-old identical triplets, Rachel, Nicole, and Alexa.
    Dr. Anderson serves as chief of the Division of Hematologic Neoplasia, director of the Jerome Lipper Multiple Myeloma Center, and vice chair of the Joint Program in Transfusion Medicine at Dana-Farber.
    In his four decades of practice and research, including 32 years at Dana-Farber, Anderson has played a central role in transforming myeloma, a cancer of the bone marrow, from a near immediate death sentence to, in many cases, a chronic, manageable illness.
    From the 1970s through the ‘90s, not a single new myeloma drug made it into clinical practice. But during the last decade, Anderson has helped shepherd multiple new drugs from laboratory bench through regulatory approval and to the patient bedside.
    6 min
  • D&K - Laurie H. Glimcher, MD, President and CEO, Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medica
    Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research
    Dr. Glimcher speaks nationally and internationally on cancer, immunology, and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.
    Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science.
    She was the first female to be appointed as Dean of Weill Cornell Medicine in New York and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute in Boston.
    9 min
  • D&K - Laurie H. Glimcher, MD, President and CEO, Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center and the Richard and Susan Smith Professor of Medicine at Harvard Medica
    Dr. Glimcher is a distinguished immunologist, widely renowned for her work in one of the most promising areas of cancer research
    Dr. Glimcher speaks nationally and internationally on cancer, immunology, and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.
    Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women in science.
    She was the first female to be appointed as Dean of Weill Cornell Medicine in New York and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute in Boston.
    9 min
  • OMF - Ava Santos, 7, Type B-cell acute lymphoblastic leukemia, Windham, NH with her parents, Marie and Kevin 8-21-18

    Ava began to complain of ear pain, and when her family brought her to the doctor, they diagnosed her with an ear infection and prescribed amoxicillin. After taking the amoxicillin, Ava broke out from head-to-toe in purple spots, and it is unknown to this day if she is allergic to amoxicillin or if was the leukemia.

    Ava began complaining about throat pain, which led them back to the doctor for another prescription—this time it was determined it was strep throat. A few days after she started taking the clindamycin, Ava began having leg pain which doctors said could be from strep.

    The pain continued and finally in March 2016, within hours of arriving at the ER, Ava and her family were informed that she had leukemia.

    After Ava's diagnosis, she was in the hospital for 2 months. In May 2016, she began treatment at the Jimmy Fund Clinic, which would last for the next two years. Ava had weekly chemotherapy treatments administered through her port, as well as oral chemotherapy drugs and steroids at home. Ava had her last treatment in April 2018, and had her port removed in May 2018.

    Ava is an only child but has lots of cousins.

    Ava started to play lacrosse this past spring and is eagerly looking forward to going back to gymnastics in the fall. She was unable to participate with her diagnosis. Ava loves to swim and play with her friends. She loves to go to amusement parks -- Canobie Lake is her favorite.

    Ava is looking forward to joining more sports teams and getting back into her normal routine.

    She is looking forward to starting second grade in the fall.

    9 min
  • OMF - Brian Boyle, 33, chronic myeloid leukemia, Hingham with Dr. Richard Stone, director of the adult leukemia program, Dana-Farber 8-21-18

    Brian Boyle is a professional ice hockey player, currently playing for the New Jersey Devils. He is one of 13 children and grew up in Hingham. Brian attended St. Sebastian’s School, and then went on to play four years of ice hockey at Boston College. He was drafted to the Los Angeles Kings out of college.

    Brian’s professional hockey career was thrown off course when he was diagnosed with chronic myeloid leukemia in September 2017. He had no symptoms of cancer other than a “steady decline” in energy level. It wasn’t until a blood test, conducted in a team physical, that he discovered the cancer.

    Throughout his treatment, Brian had to take 2 pills a day on an empty stomach. He felt some controllable side effects from his medication, but only missed 10 games throughout the course of his treatment.

    After his diagnosis, Brian had a different perspective on hockey and life. He realized that

    nothing was guaranteed and began to appreciate the smaller moments in life. When he scored his first goal after returning to the Devils, Brian teared up as he celebrated. He says that this was the first time he had ever cried after scoring.

    Brian is supported by his wife, Lauren, his two-year-old son, infant daughter, and his parents, Artie and Judy.

    Brian will be throwing out the first pitch tonight.

    Dr. Stone received his MD in 1981 from Harvard Medical School, his internal medicine residency training at Brigham and Women's Hospital, and his hematology-oncology fellowship at DFCI. He is currently the Director of the Adult Acute Leukemia Program at DFCI, serves on the Medical Oncology Board of the American Board of Internal Medicine, and is vice chair of the Leukemia Core Committee for the national cooperative trials group Cancer and Leukemia Group B.

    12 min
  • OMF - Calliope "Callie" Carney, 2, acute myeloid leukemia, Methuen with her parents, Clinton and Kaitlynne, and older sister, Penny 8-21-18

    In February 2017, Callie was exposed to whooping cough at her daycare. Her family took her to the hospital for treatment. She had her nose swabbed and it came back covered in blood. The doctors assured the family that it was most likely due to irritated sinuses.

    Callie’s bloodwork showed a low platelet count. Prior to developing whooping cough, Callie had been developing freckles. These freckles were petechiae which are small little red/purple dots that indicate low platelets.  The following week, they were introduced to a hematologist and he diagnosed her with ITP, a blood clotting disorder.

    From February through April, Callie experienced several nose bleeds, large bruises, more petechiae, and her colds seemed to be getting worse and worse.  In April 2017, Callie’s bone marrow biopsy showed AML.

    Callie received two regimens of chemotherapy throughout the months of April, May and June. Callie did extremely well during these months. She has so much energy and was so happy and full of life which gave her family hope.

    In July, Callie was able to visit home for a week before her bone marrow transplant. When Callie return to the hospital she endured a harsh 10-day chemotherapy regimen to help prepare her body to receive her new stem cells. This was very hard on her body and she became very ill. On July 10th, Callie had her transplant. It took her about 2 weeks to recover from everything. She mostly spelt and depending on a morphine drip to keep her comfortable.

    As soon as Callie body engrafted or accepted the new stem cells, Callie’s recovery was remarkable. By the 2nd week of August 2017 Callie was discharged and sent home! Her parents say it was more terrifying than coming home for the first time as new parents.

    Callie's hobbies include playing on her Kindle, playing with her "sissy," loving her dog, Yager, and cooking in her kitchen.

    Callie hopes to live a long and healthy life and is eternally grateful for her team of nurses and doctors, specifically, Dr. Suzanne Forrest, Dr. Kimberly Davies, and Dr. Michelle Lee. Her family would also like to thank the anonymous donor who bravely donated to Callie and saved her life.

    7 min
  • OMF - Calliope "Callie" Carney, 2, acute myeloid leukemia, Methuen with her parents, Clinton and Kaitlynne, and older sister, Penny 8-21-18
    In February 2017, Callie was exposed to whooping cough at her daycare. Her family took her to the hospital for treatment. She had her nose swabbed and it came back covered in blood. The doctors assured the family that it was most likely due to irritated sinuses.
    Callie’s bloodwork showed a low platelet count. Prior to developing whooping cough, Callie had been developing freckles. These freckles were petechiae which are small little red/purple dots that indicate low platelets.  The following week, they were introduced to a hematologist and he diagnosed her with ITP, a blood clotting disorder.
    From February through April, Callie experienced several nose bleeds, large bruises, more petechiae, and her colds seemed to be getting worse and worse.  In April 2017, Callie’s bone marrow biopsy showed AML.
    Callie received two regimens of chemotherapy throughout the months of April, May and June. Callie did extremely well during these months. She has so much energy and was so happy and full of life which gave her family hope.
    In July, Callie was able to visit home for a week before her bone marrow transplant. When Callie return to the hospital she endured a harsh 10-day chemotherapy regimen to help prepare her body to receive her new stem cells. This was very hard on her body and she became very ill. On July 10th, Callie had her transplant. It took her about 2 weeks to recover from everything. She mostly spelt and depending on a morphine drip to keep her comfortable.
    As soon as Callie body engrafted or accepted the new stem cells, Callie’s recovery was remarkable. By the 2nd week of August 2017 Callie was discharged and sent home! Her parents say it was more terrifying than coming home for the first time as new parents.
    Callie's hobbies include playing on her Kindle, playing with her "sissy," loving her dog, Yager, and cooking in her kitchen.
    Callie hopes to live a long and healthy life and is eternally grateful for her team of nurses and doctors, specifically, Dr. Suzanne Forrest, Dr. Kimberly Davies, and Dr. Michelle Lee. Her family would also like to thank the anonymous donor who bravely donated to Callie and saved her life.
    7 min
  • OMF - Ava Santos, 7, Type B-cell acute lymphoblastic leukemia, Windham, NH with her parents, Marie and Kevin 8-21-18
    Ava began to complain of ear pain, and when her family brought her to the doctor, they diagnosed her with an ear infection and prescribed amoxicillin. After taking the amoxicillin, Ava broke out from head-to-toe in purple spots, and it is unknown to this day if she is allergic to amoxicillin or if was the leukemia.
    Ava began complaining about throat pain, which led them back to the doctor for another prescription—this time it was determined it was strep throat. A few days after she started taking the clindamycin, Ava began having leg pain which doctors said could be from strep.
    The pain continued and finally in March 2016, within hours of arriving at the ER, Ava and her family were informed that she had leukemia.
    After Ava's diagnosis, she was in the hospital for 2 months. In May 2016, she began treatment at the Jimmy Fund Clinic, which would last for the next two years. Ava had weekly chemotherapy treatments administered through her port, as well as oral chemotherapy drugs and steroids at home. Ava had her last treatment in April 2018, and had her port removed in May 2018.
    Ava is an only child but has lots of cousins.
    Ava started to play lacrosse this past spring and is eagerly looking forward to going back to gymnastics in the fall. She was unable to participate with her diagnosis. Ava loves to swim and play with her friends. She loves to go to amusement parks -- Canobie Lake is her favorite.
    Ava is looking forward to joining more sports teams and getting back into her normal routine.
    She is looking forward to starting second grade in the fall.
    9 min

About WEEI/NESN Jimmy Fund Radio-Telethon

From the publisher's feed

Hear stories of hope and inspiration for a cancer-free future from the annual WEEI/NESN Jimmy Fund Radio-Telethon presented by Arbella Insurance.